Abstract
Aspirin is currently recommended from 12 weeks gestation until the birth of the baby for women with one high, or two moderate risk factors for pre-eclampsia, to reduce the risk of developing the condition. There is evidence to suggest aspirin use in pregnancy potentially reduces the risk of preterm birth and small for gestational age or fetal growth restricted babies. For women with recurrent pregnancy loss associated with anti-phospholipid syndrome, aspirin is recommended in combination with heparin. In this review, we discuss the history of aspirin use and its application to improving pregnancy outcomes. We also highlight the current evidence surrounding aspirin use in pregnancy and explore avenues for further research.
Original language | English |
---|---|
Pages (from-to) | 75-80 |
Journal | Obstetrics, Gynaecology and Reproductive Medicine |
Volume | 33 |
Issue number | 3 |
Early online date | 14 Jan 2023 |
DOIs | |
Publication status | Published - Mar 2023 |